Aristo Bio-Tech & Lifescience Complete Financial Statements
In FYNone, Aristo Bio-Tech & Lifescience (ARISTO) reported revenue ₹0 Cr, net profit ₹0 Cr and EPS ₹0.00, with a net profit margin of 1.9% and ROE of 15.6%. Full financial statements from FY2016 to FY2026 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Analyse ARISTO FII DII holdings to track promoter, FII and institutional holdings.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
ARISTO Revenue, Net Profit & EBITDA — Year-on-Year Growth
ARISTO YoY (March 2026 vs Period) — revenue -100.0%, net profit -100.0%, EBITDA -100.0%, expenses -100.0%. Also explore ARISTO stock price history to track price trends across different timeframes.
ARISTO Income Statement — Revenue, EBITDA & Net Profit
Aristo Bio-Tech & Lifescience revenue ₹0 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹0.00 (None) — net profit margin 1.9%. For live price, earnings ratios and company overview, see Aristo Bio-Tech & Lifescience share price chart.
| Particulars | None | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 364 | 319 | 245 | 218 | 166 | 167 | 201 | 202 | 272 | 161 | 58 |
| Expenses | 0 | 348 | 309 | 237 | 209 | 161 | 163 | 197 | 195 | 264 | 158 | 56 |
| EBITDA | 0 | 16 | 10 | 9 | 9 | 6 | 4 | 5 | 7 | 8 | 4 | 1 |
| Operating Profit Margin % | 0.00% | 4.00% | 3.00% | 3.00% | 4.00% | 3.00% | 3.00% | 2.00% | 3.00% | 3.00% | 2.00% | 2.00% |
| Depreciation | 0 | 3 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| Interest | 0 | 4 | 2 | 2 | 3 | 2 | 2 | 3 | 2 | 2 | 1 | 1 |
| Profit Before Tax | 0 | 10 | 6 | 5 | 5 | 2 | 2 | 1 | 4 | 6 | 3 | 1 |
| Tax | 0 | 3 | 1 | 2 | 1 | 1 | 0 | 0 | 1 | 2 | 1 | 0 |
| Net Profit | 0 | 7 | 4 | 4 | 4 | 2 | 1 | 1 | 3 | 4 | 2 | 0 |
| Earnings Per Share (₹) | 0.00 | 10.55 | 5.97 | 5.72 | 6.72 | 2.93 | 2.15 | 2.02 | 5.66 | 37.41 | 18.53 | 3.98 |
ARISTO Balance Sheet — Assets, Liabilities & Shareholders' Equity
ARISTO total assets ₹155 Cr, total equity ₹45 Cr, total liabilities ₹ Cr (2026) — ROE 15.6%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 155 | 141 | 127 | 100 | 77 | 81 | 88 | 91 | 89 | 87 | 27 |
| Current Assets | 130 | 116 | 105 | 83 | 63 | 69 | 77 | 81 | 81 | 84 | 25 |
| Fixed Assets | 24 | 24 | 22 | 16 | 14 | 12 | 8 | 8 | 3 | 2 | 2 |
| Capital Work in Progress | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 2 | 0 | 0 | 0 |
| Investments | 63 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 117 | 106 | 83 | 63 | 69 | 77 | 81 | 86 | 85 | 25 |
| LIABILITIES | |||||||||||
| Total Liabilities | |||||||||||
| Current Liabilities | 8 | 8 | 10 | 10 | 11 | 12 | 11 | 7 | 11 | 5 | 0 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | 45 | 37 | 34 | 30 | 15 | 13 | 12 | 11 | 9 | 5 | 3 |
| Share Capital | 7 | 7 | 7 | 7 | 5 | 5 | 5 | 5 | 1 | 1 | 1 |
| Reserves & Surplus | 38 | 31 | 27 | 23 | 10 | 8 | 7 | 6 | 8 | 4 | 2 |
ARISTO Cash Flow Statement — Operating, Investing & Financing
Aristo Bio-Tech & Lifescience operating cash flow ₹10 Cr, investing ₹-5 Cr, financing ₹-4 Cr, net cash flow ₹1 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 10 | 8 | -3 | 7 | 2 | 1 | 8 | 1 | -4 |
| Investing Activities | -5 | -7 | -4 | -3 | -2 | -2 | -2 | -5 | 0 |
| Financing Activities | -4 | -2 | 8 | -3 | -1 | 1 | -6 | 4 | 4 |
| Net Cash Flow | 1 | -1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |